Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 11/20 | 0.71 |
| ▸ | GABBR1 | Q9UBS5 | 11/20 | 0.71 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.46 |
| ▸ | AXL | P30530 | 3/20 | 0.46 |
| ▸ | MERTK | Q12866 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.42 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25399731 | 1.00 | GABBR2 (0.71) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL3111419 | 0.83 | GABBR2 (1.00) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL3118358 | 0.83 | GABBR2 (1.00) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL3121907 | 0.82 | GABBR2 (1.00) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL3121498 | 0.72 | GABBR2 (0.67) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL3123882 | 0.72 | GABBR2 (0.60) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL13268129 | 0.72 | GABBR2 (0.79) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL3122477 | 0.70 | GABBR2 (0.78) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL3118196 | 0.70 | GABBR2 (0.62) | GABBR2GABBR1TYRO3AXLMERTK | |
| SCHEMBL3123747 | 0.69 | GABBR2 (0.75) | GABBR2GABBR1TYRO3AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| WO-2023178183-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | GABBR2 13/4885GABBR1 19/4885TYRO3 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.